Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB-B167 |
Synonyms | |
Therapy Description |
BGB-B167 is a bispecific antibody that targets CEACAM5 (CEA) and TNFRSF9 (4-1BB), which potentially induces antitumor activity (Cancer Res (2024) 84 (6_Supplement): 2371). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-B167 | BGB B167|BGBB167 | CEACAM5 Antibody 8 TNFRSF9 Antibody 32 | BGB-B167 is a bispecific antibody that targets CEACAM5 (CEA) and TNFRSF9 (4-1BB), which potentially induces antitumor activity (Cancer Res (2024) 84 (6_Supplement): 2371). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|